Oculus Innovative Sciences to Present at OneMed Forum 2010 During JP Morgan Week in San Francisco

Download as PDF

Presentation and Live Audiocast on Tuesday, January 12, 2010, at 10:45 a.m. PST

PETALUMA, Calif.--(BUSINESS WIRE)-- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), today announced that Hoji Alimi, the company's CEO and founder, will discuss the upcoming 2010 regulatory and commercial milestones during his presentation at the OneMed Forum 2010 to be held at the Sir Francis Drake Hotel in San Francisco, California. Mr. Alimi's presentation is scheduled on Tuesday, January 12, at 10:45 a.m. PST, with a breakout session to immediately follow.

To listen to the live audiocast, please visit www.onemedplace.com/onemedforum/ at least 15 minutes early to download any necessary software. Participation in the conference is by invitation only. For more information on the conference, please contact OneMed at www.onemedplace.com.

About Oculus Innovative Sciences

Oculus Innovative Sciences develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, which includes new formulations designed to significantly reduce the need for antibiotics as it reduces infections. The Microcyn Technology platform features a biocompatible, shelf-stable solution that is currently commercialized in the United States, Europe, India, China and Mexico and select Middle East countries under various country-specific regulatory clearances and approvals. Several solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores, increase blood flow to the wound site, and reduce both inflammation and pain while assisting in faster wound closure. The company's headquarters are in Petaluma, California, with operations in Latin America. More information can be found at www.oculusis.com.

Oculus Innovative Sciences, Microcyn, Dermacyn and Vetericyn are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners. 


    Source: Oculus Innovative Sciences, Inc.

Released January 7, 2010